BC Week In Review | Nov 10, 2014
Clinical News

NKTT120 regulatory update

FDA granted Fast Track designation to NKTT120 from NKT to treat sickle cell disease. Next year, the company plans to start Phase IIb testing of the humanized mAb targeting invariant NK T (iNKT) cells for...
BC Week In Review | Jan 13, 2014
Clinical News

NKTT120: Interim Phase I data

Interim data from 11 patients with stable sickle cell disease in an open-label, dose-escalation, U.S. Phase I trial showed that single doses of 0.001, 0.003, 0.01 and 0.03 mg/kg NKTT120 were well tolerated with no...
BC Week In Review | Oct 11, 2010
Company News

NKT Therapeutics management update

NKT Therapeutics Inc. , Waltham, Mass.   Business: Inflammation, Cancer, Autoimmune   Hired: Barbara Finck as CMO, formerly SVP of R&D and CMO at Osprey Pharmaceuticals U.S.A. Inc.  ...
BC Innovations | Jun 10, 2010
Distillery Techniques

Technology: Drug platforms

Approach Summary Licensing status Publication and contact information Drug platforms Enzymatic adjuvant to NK cell vaccination In vitro, cell culture and mouse studies suggest that fatty acid amide hydrolase (FAAH) could be a useful vaccine...
BioCentury | Jan 25, 2010
Finance

SVLS closes V fund

While the pace of venture fundraising suggests some VCs are having trouble raising new funds, SV Life Sciences has closed its fifth fund on target at $400 million, with the prospects of surpassing $500 million....
BC Week In Review | Oct 26, 2009
Company News

NKT Therapeutics, Kyowa Hakko Kirin deal

NKT received a non-exclusive license from Kyowa's BioWa Inc. subsidiary to use Potelligent technology to research, develop and commercialize antibodies against natural killer T cells. Potelligent increases antibody-dependent cellular cytotoxicity (ADCC). ). BioWa will receive...
BC Week In Review | Apr 6, 2009
Company News

NKT Therapeutics board of directors update

NKT Therapeutics Inc. , Newton, Mass.   Business: Inflammation, Cancer, Autoimmune   Appointed: Michael Ross, managing partner at SV Life Sciences; and Joseph Amprey, senior managing director of MedImmune Ventures  ...
Items per page:
1 - 7 of 7
BC Week In Review | Nov 10, 2014
Clinical News

NKTT120 regulatory update

FDA granted Fast Track designation to NKTT120 from NKT to treat sickle cell disease. Next year, the company plans to start Phase IIb testing of the humanized mAb targeting invariant NK T (iNKT) cells for...
BC Week In Review | Jan 13, 2014
Clinical News

NKTT120: Interim Phase I data

Interim data from 11 patients with stable sickle cell disease in an open-label, dose-escalation, U.S. Phase I trial showed that single doses of 0.001, 0.003, 0.01 and 0.03 mg/kg NKTT120 were well tolerated with no...
BC Week In Review | Oct 11, 2010
Company News

NKT Therapeutics management update

NKT Therapeutics Inc. , Waltham, Mass.   Business: Inflammation, Cancer, Autoimmune   Hired: Barbara Finck as CMO, formerly SVP of R&D and CMO at Osprey Pharmaceuticals U.S.A. Inc.  ...
BC Innovations | Jun 10, 2010
Distillery Techniques

Technology: Drug platforms

Approach Summary Licensing status Publication and contact information Drug platforms Enzymatic adjuvant to NK cell vaccination In vitro, cell culture and mouse studies suggest that fatty acid amide hydrolase (FAAH) could be a useful vaccine...
BioCentury | Jan 25, 2010
Finance

SVLS closes V fund

While the pace of venture fundraising suggests some VCs are having trouble raising new funds, SV Life Sciences has closed its fifth fund on target at $400 million, with the prospects of surpassing $500 million....
BC Week In Review | Oct 26, 2009
Company News

NKT Therapeutics, Kyowa Hakko Kirin deal

NKT received a non-exclusive license from Kyowa's BioWa Inc. subsidiary to use Potelligent technology to research, develop and commercialize antibodies against natural killer T cells. Potelligent increases antibody-dependent cellular cytotoxicity (ADCC). ). BioWa will receive...
BC Week In Review | Apr 6, 2009
Company News

NKT Therapeutics board of directors update

NKT Therapeutics Inc. , Newton, Mass.   Business: Inflammation, Cancer, Autoimmune   Appointed: Michael Ross, managing partner at SV Life Sciences; and Joseph Amprey, senior managing director of MedImmune Ventures  ...
Items per page:
1 - 7 of 7